Xencor (XNCR) Expected to Announce Earnings on Wednesday

Xencor (NASDAQ:XNCR) is anticipated to issue its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.65) per share and revenue of $27.8550 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.55. The business had revenue of $28.24 million during the quarter, compared to analysts’ expectations of $29.97 million. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The business’s revenue was down 46.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.62) EPS. On average, analysts expect Xencor to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Xencor Price Performance

Shares of XNCR stock opened at $12.69 on Monday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.25 and a current ratio of 6.25. Xencor has a fifty-two week low of $6.92 and a fifty-two week high of $18.69. The firm has a market cap of $940.71 million, a P/E ratio of -10.23 and a beta of 0.93. The business’s 50 day moving average price is $12.21 and its 200-day moving average price is $13.64.

Insider Activity at Xencor

In related news, CEO Bassil I. Dahiyat sold 14,870 shares of the business’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $11.25, for a total transaction of $167,287.50. Following the sale, the chief executive officer owned 552,922 shares of the company’s stock, valued at $6,220,372.50. The trade was a 2.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Celia Eckert sold 3,244 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $11.25, for a total transaction of $36,495.00. Following the transaction, the senior vice president directly owned 78,685 shares of the company’s stock, valued at $885,206.25. This represents a 3.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 44,020 shares of company stock valued at $499,817 in the last three months. Company insiders own 5.23% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC boosted its holdings in Xencor by 118.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 3,018 shares in the last quarter. E Fund Management Co. Ltd. bought a new position in shares of Xencor during the second quarter valued at $79,000. iSAM Funds UK Ltd bought a new position in shares of Xencor during the second quarter valued at $122,000. Prelude Capital Management LLC purchased a new position in shares of Xencor in the 3rd quarter worth about $139,000. Finally, Creative Planning raised its position in shares of Xencor by 25.3% in the 2nd quarter. Creative Planning now owns 18,130 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 3,661 shares during the last quarter.

Analysts Set New Price Targets

XNCR has been the subject of a number of research analyst reports. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $13.00 price target (down from $18.00) on shares of Xencor in a research note on Tuesday, March 24th. Wall Street Zen raised shares of Xencor from a “sell” rating to a “hold” rating in a research report on Saturday, April 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Friday, March 27th. Finally, Barclays raised their price objective on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $24.38.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.